Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2021

View Archived Issues

Asarina reports phase IIa topline data on sepranolone in menstrual migraine

I-Mab receives Chinese clearance to conduct phase Ib study of felzartamab in SLE

China NMPA clears phase I trial of InnoCare's ICP-033 for solid tumors

Lynk cleared to begin clinical trials in China with LNK-01003 for inflammatory bowel disease

SIRPalpha-deficient macrophages orchestrate a potent antitumor immune response under radiotherapy

TPR-1 shows antibacterial activity in a panel of F. tularensis strains and a lethal infection model

Peking University Third Hospital, Chigenovo Co. describe therapies including CYP4V2 and RdCVF

Albireo synthesizes new IBAT/LBAT inhibitors

New TLR7/8/9 antagonists identified at Roche

New HIF-2alpha inhibitors identified at Arcus Biosciences

BCN Peptides patents peptides and peptide dimers derived from ADAM 12

Chemoattenuated Pf sporozoite-based vaccine shows efficacy, good tolerance and immunogenicity

First data presented for diarylquinoline TBAJ-876 as antimycobacterial compound

SAN-711 shows promising activity in rat model of orofacial pain

AstraZeneca initiates phase II/III study of COVID-19 variant vaccine AZD-2816

First-in-human data from ongoing ALPHA2 study of ALLO-501A

New resveratrol derivatives against H. pylori resistance

Neurotrophic signaling deficiency exacerbates Alzheimer's risk factors

Kymera reports interim phase I SAD data on IRAK-4 degrader KT-474

iLeukPulm study of inhaled Leukine for COVID-19 shows improved oxygenation

DSMB recommends continuation of phase Ib study of microbiome ecosystem therapy MaaT-033 in AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...